Research programme: GR DD101 - ERYtech Pharma

Drug Profile

Research programme: GR DD101 - ERYtech Pharma

Alternative Names: GR-DD101

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ERYtech Pharma
  • Class Bisphosphonates
  • Mechanism of Action Bone resorption factor inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Bone cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Bone-cancer in France (Parenteral)
  • 25 Feb 2009 This programme is available for co-development (
  • 25 Feb 2009 Early research in Bone cancer in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top